Conditions: Breast Carcinoma; Carcinoma of Unknown Primary; Endometrial Carcinoma; Esophageal Carcinoma; Liver Failure; Lung Carcinoma; Malignant Head and Neck Neoplasm; Malignant Testicular Neoplasm; Melanoma; Metastatic Malignant Neoplasm; Ovarian Carcinoma; Renal Failure; Unresectable Malignant Neoplasm; Urothelial Carcinoma
Interventions: Drug: Carboplatin; Other: Laboratory Biomarker Analysis; Drug: Paclitaxel; Other: Pharmacological Study; Drug: Veliparib
Sponsors: National Cancer Institute (NCI); Abbott
Active, not **RECRUITING NOW**
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.